Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men

Clinical Endocrinology

Volumn 47, Issue 6, 1997, Pages 727-737

  Arver, Stefan ^a,b   Dobs, Adrian S ^c   Meikle, A Wayne ^d   Caramelli, Kim E ^e   Rajaram, Lakshminaryan ^e   Sanders, Steven W ^e   Mazer, Norman A ^e,f  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e TheraTech Inc   (United States)

^f UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ADULT; ANDROGEN THERAPY; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOGONADISM; MALE; MULTICENTER STUDY; PRIORITY JOURNAL;

EID: 0031469651     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1997.3071113.x     Document Type: Article

References (29)

1. Aloia, J.F. & Field, R.A. (1976) The effect of androgens and related substances on carbohydrate metabolism, lipid metabolism and diabetes mellilus. Pharmacology and Therapeutics, 1, 241-257.
2. Arver, S., Dobs, A.S., Meikle, A.W., Allen, R.P., Sanders, S.W. & Mazer, N.A. (1996) Improvement of sexual function in testosterone deficient men treated for one year with a permeation enhanced testosterone transdermal system. The Journal of Urology, 155, 1604-1608.
3. Arver, S., Dobs, A.S., Meikle, A.W., Sanders, S.W., Caramelli, K.E., Lakshminaryan, R. & Mazer, N.A. (1994) Hormone levels, endocrine responses and sexual function in hypogonadal men treated for one year with a non-serotal testosterone transdermal delivery system (T-TDS). Program of The Endocrine Society. Anaheim, CA. (June 15-18) Abstract, p. 1307.
4. Bagatell, C.J., Knopp, R.H., Vale, W.W., Rivier, J.E. & Bremner, W.J. (1992) Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels. Annals of Internal Medicine, 116, 967-973.
5. Barefoot, J.C., Peterson, B.L., Dahlstrom, W.G., Seigler, I.C., Anderson, N.B. & Williams, R.B. Jr (1991) Hostility patterns and health implications: correlates of Cook-Medley Hostility Scale scores in a national survey. Health Psychology, 10, 18-24.
6. Beck, A.T., Ward, C.H., Mendelson, M., Mock, J. & Erbaugh, J. (1961) An inventory tor measuring depression. Archives of General Psychiatry, 4, 561-571.
7. Bizzarro, A., Valentini, G., DiMartino, G., Daponte, A., DeBellis, A. & Iacono, G. (1987) Influence of testosterone therapy on clinical and immunological features of autoimmune diseases associated with Klinefelter's syndrome. Journal of Clinical Endocrinology and Metabolism, 64, 32-36.
8. Cardinale, V. & Chi, J.C. (Eds) (1996) Drug Topics Red Book (100th Edn.) Medical Economics Data Publication.
9. Catapres, T.T.S., ® (1995) Physician's Desk Reference, p. 637.
10. Derogatis, L.R. (1975) The Affects Balance Scale, Clinical Psychometric Research, Baltimore.
11. Estraderm® (1995) Physician's Desk Reference, p. 885.
12. Glass, A.R., Swerdloff, R.S., Bray, G.A., et al. (1977) Low serum testosterone and sex-hormone -binding globulin in massively obese males. Journal of Clinical Endocrinology and Metabolism, 45, 1211-1219.
13. Gooren, L. & Polderman, D. (1990) Safety aspects of androgen therapy. In Testosterone, action deficiency, substitution (eds. E. Nieschlag & H.M. Behre), pp. 182-203. Springer-Verlag, Berlin.
14. Hogan, D.J. & Maibach, H.I. (1990) Adverse dermatologic reactions to transdermal drug delivery systems. Journal of the American Academy of Dermatology, 22, 811-814.
15. Horning, J.R., Zawada, E.T. Jr. Simmons, J.L., Williams, L. & McNulty, R. (1988) Efficacy and safety of two-year therapy with transdermal clonidine for essential hypertension. Chest. 93, 941-945.
16. Marin, P., Holmang, S., Jonsson, L., Sjostrom, L., Kvist, H., Holm, G., Linstedt, G. & Bjorntorp, P. (1992) The effect of testosterone treatment on body composition and metabolism in middle-aged obese men. Internationalernational Journal of Obesity, 16, 991-997.
17. Mazer, N.A., Heiber, W.E., Moellmer, J.F., Meikle, A.W. & Stingham, J.D. (1992) Enhanced transdermal delivery of testosterone: a new physiological approach for androgen replacement in hypogonadal men. Journal of Controlled Release, 19, 347-362.
18. Mazer, N.A., Sanders, S.W., Ebert, C.D. & Meikle, A.W. (1993) Mimicking the circadian pattern of testosterone and metabolite levels with an enhanced transdermal delivery system. In: Pulsatile Drug Delivery: Current Applications and Future Trends (eds. R. Gurny, H.E. Junginger & N.A. Peppas), pp. 73-97. Wissenschaftliche Verlagsges mbH, Stuttgart.
19. Meikle, A.W., Mazer, N.A., Moellmer, J.F., Stringham, J.D., Tolman, K.G., Sanders, S.W. & Odell, W.D. (1992) Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 74, 623-628.
20. Meikle, A.W., Arver, S., Dobs, A.S., Hoover, D.R., Sanders, S.W. & Mazer, N.A. (1993) Application site influences on the enhanced transdermal delivery of testosterone to hypogonadal men. Program of The Endocrine Society Las Vegas, Nevada (June 9-12). Abstract, p. 383.
21. Meikle, A.W., Arver, S., Dobs, A.S., Sanders, S.W., Rajaram, L. & Mazer, N.A. (1996) Pharmacokinetics and Metabolism of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men: Influence of Application Site - A Clinical Research Center Study. Journal of Clinical Endocrinology and Metabolism, 81, 1832-1840.
22. Meikle, A.W., Arver, S., Dobs, A.S., Adolfsson, J., Sanders, S.W., Middleton, R.G., Stephenson, R.A., Hoover, D.R., Ravaram, L. & Mazer, N.A. (1997) Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology, 49, 191-196.
23. Mooradian, A.D., Morley, J.E. & Korenman, S.G. (1987) Biological actions of androgens. Endocrine Reviews, 8, 1-28.
24. Resko, J.A. & Eik-Nes, K.B. (1996) Diurnal testosterone levels in peripheral plasma of human male subjects. Journal of Clinical Endocrinology and Metabolism, 26, 573-576.
25. Stepan, J.J., Lachman, M., Zverina, J., Pacovsky, V. & Baylink, D.J. (1989) Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. Journal of Clinical Endocrinology and Metabolism, 69, 523-527.
26. Tellegen, A. (1982) A brief manual for the differential personality questionnaire. The University of Minnesota Press, Minneapolis.
27. Welsh, R. (Ed.) (1996) Fee and Coding Standard: National Pricing Guide for Setting Fees. Medicode Inc.
28. Zumoff, B., Strain, G.W., Kream, J., O'Connor, J., Rosenfeld, R.S., Levin, J. & Fukushima, D.K. (1982) Journal of Clinical Endocrinology and Metabolism, 54, 534-538.
29. Zumoff, B., Strain, G.W., Miller, L.K., Rosner, W., Senie, R., Seres, D.S. & Rosenfeld, R.S. (1990) Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. Journal of Clinical Endocrinology and Metabolism, 71, 929-931.